Pure Global AI
NCT06207851Recruiting

Transcatheter Arterial Micro-Embolization (TAME) Using Nexsphere-F in Patients With Chronic Pain in Elbow or Wrist

A Single-arm, Single-center, Open-label, Pilot Clinical Study to Evaluate the Efficacy and Safety of Transcatheter Arterial Micro-Embolization (TAME) Using Nexsphere-F in Patients With Chronic Pain in Elbow or Wrist
Next Biomedical Co., Ltd.ClinicalTrials.govdeviceDevice trial
Verified
Study focus
Disease/Condition
Osteoarthritis
Drug/Device/Intervention
Transcatheter Arterial Micro-Embolization
Study type
Interventional
Intervention type
device
Sponsor & location
Primary sponsor
Next Biomedical Co., Ltd.
Location
Seoul, South Korea
Timeline & enrollment
Phase
N/A
Start date
Jul 13, 2023
End date
Jul 13, 2026
Enrollment
38 participants
Primary outcome

Rate of subjects with a 50% or more reduction in QuickDASH Score Change

Summary

In patients with chronic elbow or wrist pain, the pain is controlled by conventional
 conservative therapy The pain reduction effect of Nexsphere-F embolization in patients who
 need additional treatment It is intended to demonstrate safety.

ICD-10 classifications
Other hypertrophic osteoarthropathyOther specified osteochondropathiesPolyarthritis, unspecifiedOther osteochondropathiesOsteochondritis dissecans
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06207851
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT06207851 through Pure Global AI's free database. This phase not specified trial is sponsored by Next Biomedical Co., Ltd. and is currently Recruiting. The study focuses on Osteoarthritis. Target enrollment is 38 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.